Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2352-3026(21)00100-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).
Wellcome Open Res
August 2024
Medical Research Council Clinical Trials, University College London, London, England, WC1V 6LJ, UK.
Article Synopsis
- African children with severe malaria have high death rates, particularly within the first 24 hours of hospital admission, largely due to lactic acidosis caused by parasite sequestration.
- Sevuparin, a heparin-like drug, may improve outcomes by preventing merozoite invasion and enhancing blood flow in infected individuals when administered early during admission.
- A Phase I trial in Kenya and Zambia will evaluate the safety and optimal dosing of sevuparin in children with severe malaria and lactic acidosis, with results expected to inform future Phase II trials.
Recent developments in antimalarial drug discovery.
Bioorg Med Chem
June 2023
Department of Pharmacy, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda.
Although malaria remains a big burden to many countries that it threatens their socio-economic stability, particularly in the countries where malaria is endemic, there have been great efforts to eradicate this disease with both successes and failures. For example, there has been a great improvement in malaria prevention and treatment methods with a net reduction in infection and mortality rates. However, the disease remains a global threat in terms of the number of people affected because it is one of the infectious diseases that has the highest prevalence rate, especially in Africa where the deadly Plasmodium falciparum is still widely spread.
View Article and Find Full Text PDFSevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Haematol
May 2021
Modus Therapeutics, Stockholm, Sweden.
Background: There are no approved treatments for vaso-occlusive crises in sickle cell disease. Sevuparin is a novel non-anticoagulant low molecular weight heparinoid, with anti-adhesive properties. In this study, we tested whether sevuparin could shorten vaso-occlusive crisis duration in hospitalised patients with sickle cell disease.
View Article and Find Full Text PDFSevuparin trial for acute pain in sickle cell disease: the dog that did not bark.
Lancet Haematol
May 2021
UNC Blood Research Center, Chapel Hill, NC 27599, USA.
Drugs in Development for Malaria.
Drugs
June 2018
Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.
The last two decades have seen a surge in antimalarial drug development with product development partnerships taking a leading role. Resistance of Plasmodium falciparum to the artemisinin derivatives, piperaquine and mefloquine in Southeast Asia means new antimalarials are needed with some urgency. There are at least 13 agents in clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!